TheraRadar
← Back
Data updated: Jun 28, 2026

RK PHARMA

Generics

RK PHARMA is a generic drug manufacturer focused on Immunology, Oncology, Neurology.

1999
Since
13
Drugs
-
Trials
0
New Drugs (2yr)

RK PHARMA's Key Drugs

RK PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

RK PHARMA's Recent FDA Approvals

New NDA/BLA approvals for RK PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

RK PHARMA's Therapeutic Areas

RK PHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 20%
1 drugs
Oncology 20%
1 drugs
Neurology 20%
1 drugs
Metabolic 20%
1 drugs
Cardiovascular 20%
1 drugs

RK PHARMA's Top Competitors

RK PHARMA's closest competitors by therapeutic-area and drug-target overlap include Sanofi, Eli Lilly, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

RK PHARMA Pipeline Snapshot

Active clinical trials for RK PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling